相关实验视频

Updated: May 6, 2026

Short Session High Intensity Interval Training and Treadmill Assessment in Aged Mice

Short Session High Intensity Interval Training and Treadmill Assessment in Aged Mice

Published on: February 2, 2019

协同拯救:HIIT和草药盟友可以在老鼠中逆转NAFLD损伤

Ehsan Arabzadeh¹, Amir Sarshin², Foad Feizolahi²

¹Exercise Physiology Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Journal of molecular histology

|April 5, 2025

概括

运动和乳,香草和子补充剂的组合有效地治疗大鼠的非酒精性脂肪肝疾病 (NAFLD),通过改善肝脏健康和功能.

科学领域:

生物化学生物化学
代谢障碍代谢障碍代谢障碍
运动生理学运动生理学

背景情况:

非酒精性脂肪性肝病 (NAFLD) 涉及肝脏中的脂肪积累,可能导致严重损伤.
高脂肪饮食 (HFD) 诱导NAFLD,导致脂质不良,氧化应激,以及肝脏组织中关键代谢标记的改变.
目前针对NAFLD的治疗方法往往存在局限性,需要探索新的治疗策略.

研究的目的:

调查高强度间歇训练 (HIIT) 和一种特定的草药补充剂混合物对NAFLD小鼠模型中的肝脏健康的影响.
评估运动和补充剂对肝脏主要代谢物和氧化应激指标的综合影响.
确定HIIT和补充剂是否可以逆转HFD诱导的肝损伤和代谢功能障碍.

主要方法:

成年雄性Wistar大鼠被食高脂肪饮食 (HFD) 6周以诱导NAFLD.
在诱导后,大鼠被分为四组:仅HFD,HIIT,补充剂 (乳,西瓜,子) 和联合HIIT和补充剂.
干预持续了4周,之后分析了肝脏组织的代谢物,氧化应激标记物 (氨酸,超氧化物脱酶) 和基因/蛋白质表达 (PI3K,UCP2,PGC-1α).

主要成果:

HFD成功诱导了NAFLD,其特征是脂质不良,肝损伤,恶性二甲酸,UCP2,PI3K增加,SOD和PGC-1α减少.
无论是HIIT还是补充剂都单独改善了这些标记物,但联合干预表明NAFLD诱导的变化最显著地逆转.
组合疗法显著提高了氧化应激指数,改善了脂质配置文件,并有利地调节了PI3K,UCP2和PGC-1α表达和蛋白质水平.

结论:

结合高强度间歇训练和牛,香草和子补充剂在治疗非酒精性脂肪肝疾病方面显示出显著的潜力.
这种协同方法有效地减轻HFD诱导的肝损伤,通过改善脂质配置,减少氧化应激,并恢复关键的代谢途径.
这些发现表明,对管理NAFLD和相关的肝脏并发症有前途的治疗策略.

关键词:

高强度间歇训练高强度间歇训练脂质特征脂质特征脂质特征这是NAFLD.氧化应激是一种氧化应激.补充补充补充

更多相关视频

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...